Many physicians who treat patients with chronic back pain lack the knowledge to identify people with axial spondyloarthritis, ...

Spondyloarthritis (SpA), if not diagnosed and treated early, often leads to significant morbidity. Unfortunately, diagnosis and implementation of therapy are frequently delayed, in many cases by ...

The global axial spondyloarthritis market is set for significant growth, with forecasts indicating a robust CAGR of 14.8% during the period from 2022 to 2028. This growth is primarily attributed to ...

New features of the Assessment of SpondyloArthritis International Society axial spondyloarthritis criteria The concept of nonradiographic axial spondyloarthritis. Recognition of a role of MRI in ...

Upadacitinib sustains its efficacy in non-radiographic axial spondyloarthritis through 2 years without presenting any new safety signals, according to data published in Arthritis Research & Therapy.

The chronic back pain of axial spondyloarthritis (axSpA) may be accompanied after diagnosis by three primary extra-musculoskeletal manifestations -- uveitis, psoriasis, or inflammatory bowel ...

Objective To investigate the effectiveness of high intensity exercises on disease activity in patients with axial spondyloarthritis (axSpA). Method Assessor blinded multicentre randomised controlled ...

Hillstar Bio, a leading biotechnology company focused on developing next-generation precision immunology therapies for ...

Patients with radiographic axial spondyloarthritis who receive ixekizumab biweekly demonstrate lower sacroiliac joint erosion and increased the backfill of new tissue through 52 weeks, according to ...